CARMEL, Ind., April 17, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today its continued partnership with Maricopa County, Arizona, for a third public health training, focused on cultural humility.
The collaboration between Syra Health and Maricopa County began with a commitment to addressing healthcare disparities through health equity training. Building upon this foundation, the partnership continued, with the successful completion of a public health training program, developed by Syra Health and known as the "Foundations of Public Health."
Most recently, Syra Health was awarded a third contract to conduct cultural humility training, in Maricopa County, which fosters inclusive and culturally competent healthcare practices. According to Rutgers University, "Cultural Competence aims to educate people on the cultural differences across groups of individuals and facilitate communication between them. First developed in the medical field, Cultural Humility expands on cultural competence and asks individuals to self-reflect on their ideas and biases related to cultural groups and identities."
"Syra Health's team members have delivered high-quality trainings to our staff and our community partners," said Shaeleen Corea, Regional Health Equity Program Specialist, Maricopa County. "I specifically would like to call out their proactive communication methods that helped avoid any potential issues and resulted in a stress-free collaboration process."
Syra Health remains dedicated to its mission of improving healthcare through innovative training solutions. "We look forward to continuing our partnership with Maricopa County," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "We also plan to expand the reach of our healthcare trainings to local, state, and federal governments across the country."
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.42 |
Daily Change: | -0.04 -8.35 |
Daily Volume: | 179,328 |
Market Cap: | US$3.740M |
December 02, 2024 November 26, 2024 October 29, 2024 September 13, 2024 August 08, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB